摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[3-amino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide

中文名称
——
中文别名
——
英文名称
N-[3-amino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide
英文别名
N-(5-amino-13,14,15-trimethoxy-8-tricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaenyl)acetamide
N-[3-amino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide化学式
CAS
——
化学式
C20H24N2O4
mdl
——
分子量
356.422
InChiKey
FGTMBXSELXOUJW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    82.8
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Colchinol derivatives as angiogenesis inhibitors
    申请人:——
    公开号:US20030195173A1
    公开(公告)日:2003-10-16
    The invention related to colchinol derivatives of the formula (I): Wherein: R 1 , R 2 and R 3 are each independently hydroxy, phosphoryloxy (—OPO 3 H 2 ), C 1-4 alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R 1 , R 2 and R 3 are C 1-4 alkoxy; A is —CO—, —C(O)O—, —CON(R 8 )— (wherein R 8 is hydrogen, C 1-4 alkyl, C 1-3 alkoxyC 1-3 alkyl, aminoC 1-3 alkyl or hydroxyC 1-3 alkyl); a is an integer from 1 to 4 inclusive; R a and R b are independently selected from hydrogen, hydroxy and amino; B is —O—, —CO—, N(R 9 )CO—, —CON(R 9 )—, —N(R 9 )C(O)O—, —N(R 9 )CON(R 10 )—, —N(R 9 )SO 2 —, —SO 2 N(R 9 )— or a direct single blond (wherein R 9 and R 10 are independently selected from hydrogen, C 1-4 alkyl, C 1-3 alkoxyC 1-3 alkyl,aminoC 1-3 alkyl and hydroxyC 1-3 alkyl); b is O or an integer from 1 to 4 inclusive, (provided that when bis O, B is a single direct bond); D is carboxy, sulpho, tetrazolyl, imidazolyl, phosphoryloxy, hydroxy, amino, N-(C 1-4 alkyl)amino, N,N-di(C 1-3 alkyl)amino, or of the formula-Y 1 (CH 2 ) 0 R 11 or —NHCH(R 12 )COOH;[wherein Y 1 is a direct single bond, —O—, —C(O)—, —N(R 13 )C(O)— or —C(O)N(R 13 )— (wherein R 13 is hydrogen, C 1-4 alkyl,C 1-3 alkoxyC 2-3 alkyl, aminoC 2-3 alkyl or hydroxyC 2-3 alkyl); e is O or an integer from 1 to 4 inclusive.
    与化学相关的发明,涉及公式(I)的秋水仙碱衍生物:其中:R1、R2和R3分别独立地为羟基、磷酸酯基(—OPO3H2)、C1-4烷氧基或羟基的体内可水解酯,但至少其中2个为C1-4烷氧基;A为—CO—、—C(O)O—、—CON(R8)—(其中R8为氢、C1-4烷基、C1-3烷氧基烷基、氨基烷基或羟基烷基);a为1到4的整数;Ra和Rb分别独立地选自氢、羟基和氨基;B为—O—、—CO—、N(R9)CO—、—CON(R9)—、—N(R9)C(O)O—、—N(R9)CON(R10)—、—N(R9)SO2—、—SO2N(R9)—或直接单键(其中R9和R10分别独立地选自氢、C1-4烷基、C1-3烷氧基烷基、氨基烷基和羟基烷基);b为O或1到4的整数,(当b为O时,B为单一直接键);D为羧基、磺酸基、四唑基、咪唑基、磷酸酯基、羟基、氨基、N-(C1-4烷基)氨基、N,N-二(C1-3烷基)氨基,或公式-Y1(CH2)0R11或—NHCH(R12)COOH;[其中Y1为直接单键、—O—、—C(O)—、—N(R13)C(O)—或—C(O)N(R13)—(其中R13为氢、C1-4烷基、C1-3烷氧基烷基、氨基烷基或羟基烷基);e为O或1到4的整数。
  • Colchinol derivatives as vascular damaging agents
    申请人:Davis D. Peter
    公开号:US20060128633A1
    公开(公告)日:2006-06-15
    The invention relates to the use of compounds of formula (I): wherein X is —C(O)—, —C(S)—, —C═NOH, or —CH(R 7 )— wherein R 7 is hydrogen, hydroxy, C 1-7 alkoxy, —OR 8 or —NR 8 R 9 (wherein R 8 is a group —Y 1 R 10 (wherein Y 1 is a direct bond, —C(O)—, —C(S)—, —S—, —C(O)O—, —C(O)NR 11 —, —SO 2 — or —SO 2 NR 12 — (wherein R 11 and R 12 , which may be the same or different, each independently represents hydrogen; C 1-3 alkyl or C 1-3 alkoxyC 2-3 alkyl) and R 10 is as defined herein, R 9 includes hydrogen; R 11 , R 12 and R 13 are as defined herein and are preferably methyl; R 4 , R 5 and R 6 are as defined herein with the proviso that R 5 is not hydroxy, alkoxy, substituted alkoxy, —OPO 3 H 2 , —O—C 1-7 alkanoyl or benzyloxy; and salts thereof in the manufacture of a medicament for use in the production of a vascular damaging effect in warm-blooded animals such as humans. The present invention further relates to compounds of the formula (I), pharmaceutical compositions containing them, processes for their preparation and to a method of treatment using the compounds to produce a vascular damaging effect in a warm-blooded animal such as a human. The compounds of formula (I) and the pharmaceutically acceptable salts thereof may be useful in the treatment of a number of disease states including cancer and rheumatoid arthritis.
    本发明涉及使用以下化合物(I)的制药用途:其中X为—C(O)—、—C(S)—、—C═NOH或—CH(R7)—,其中R7为氢、羟基、C1-7烷氧基、—OR8或—NR8R9(其中R8为—Y1R10基团,其中Y1为直接键、—C(O)—、—C(S)—、—S—、—C(O)O—、—C(O)NR11—、—SO2—或—SO2NR12—(其中R11和R12,可以相同也可以不同,各自独立地表示氢、C1-3烷基或C1-3烷氧基C2-3烷基),而R10如上所述,R9包括氢;R11、R12和R13如上所述,且最好为甲基;R4、R5和R6如上所述,但其中R5不是羟基、烷氧基、取代烷氧基、—OPO3H2、—O—C1-7烷酰基或苄氧基;以及它们的盐在制造用于在温血动物如人类中产生血管损伤效应的药物中的应用。本发明还涉及化合物(I)、含有它们的制药组合物、其制备方法以及使用这些化合物在温血动物如人类中产生血管损伤效应的治疗方法。化合物(I)及其药学上可接受的盐可以在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中有用。
  • COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS
    申请人:Angiogene Pharmaceuticals Limited
    公开号:EP1301498A1
    公开(公告)日:2003-04-16
  • US6720323B2
    申请人:——
    公开号:US6720323B2
    公开(公告)日:2004-04-13
  • US6846925B2
    申请人:——
    公开号:US6846925B2
    公开(公告)日:2005-01-25
查看更多

同类化合物

别秋水仙碱 N-乙酰基秋水仙醇甲基醚 ANG 453; N-[(5S)-6,7-二氢-9,10,11-三甲氧基-3-(磷酰氧基)-5H-二苯并[a,c]环庚烯-5-基]乙酰胺 N-[(5S)-3-(2-tert-butoxycarbonylethylcarbamoyl)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide N-[3-amino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide N-[3-((N-benzyloxycarbonylalanyl)amino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide N-[(5S)-3-(2-morpholinoethoxycarbonyl)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide N-[(5S)-3-(2-morpholinoethoxy)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide N-(1,2,3,9,10-pentamethoxy-5,6-dihydro-7H-dibenzo[a,c][7]annulen-7-yl)acetamide N-(10-fuoro-9-hydroxy-1,2,3-trimethoxy-5,6-dihydro-7H-dibenzo[a,c][7]annulen-7-yl)acetamide (5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl ethyl hydrogen phosphate N-[(5S)-3-phenoxycarbonyloxy-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide (5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl hydrogenmethylphosphonate 4-[([(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl]oxycarbonyl)amino]butanoic acid 4-[([(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl]aminocarbonyl)amino]butanoic acid 5-[{(5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl}oxycarbonyl]pentanoic acid N-[(5S)-3-(2,3-epoxypropoxy)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide N-(6-cyano-7-hydroxy-6-(ethoxymethyl)-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl)benzamide N-(6-cyano-7-hydroxy-6-(methoxymethyl)-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl)benzamide N-(6-cyano-3-fluoro-7-hydroxy-6-(isopropoxymethyl)-6,7-dihydro-5Hdibenzo[a,c][7]annulen-5-yl)benzamide ethyl 5-benzamido-7-hydroxy-6-(isopropoxymethyl)-6,7-dihydro-5Hdibenzo[a,c][7]annulene-6-carboxylate ethyl 5-benzamido-6-(ethoxymethyl)-7-hydroxy-6,7-dihydro-5H-dibenzo[a,c][7]annulene-6-carboxylate N-(6-cyano-7-hydroxy-6-(isopropoxymethyl)-6,7-dihydro-5H-dibenzo[a,c][7]annulen-5-yl)furan-2-carboxamide (5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl hydrogensulphate N-[(5S)-3-(N,N-dimethylaminoacetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide N-[(5S)-9,10,11-trimethoxy-3-([(3-morpholinopropyl)amino]carbonylamino)-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide N-[(5S)-3-phenoxycarbonylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]acetamide (5S)-5-(acetylamino)-9,10,11-trimethoxy-N-(3morpholinopropyl)-6,7-dihydro-5H-dibenzo[a,c]cycloheptene-3-carboxamide (5S)-5-(acetylamino)-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl methyl carbonate N-((1S)-2''-(8-(metoxycarbonyl)octyl)-1',2',3'-trimetoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta[3,2-f]benzofuran-1-yl)acetamide N-((1S)-2''-(pyridin-2-yl)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta[3,2-f]benzofuran-1-yl)acetamide N-((1S)-2''-(2-hydroxyethyl)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta[3,2-f]benzofuran-1-yl)acetamide N-((1S)-2''-(acetoxymethyl)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta[3,2-f]benzofuran-1-yl)acetamide N-((1S)-2''-((diethylamino)methyl)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta[3,2-f]benzofuran-1-yl)acetamide N-((1S)-2''-(1-hydroxycyclopentyl)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta[3,2-f]benzofuran-1-yl)acetamide N-((1S)-2''-(hydroxymethyl)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta[3,2-f]benzofuran-1-yl)acetamide N-((1S)-2''-(1-hydroxyethyl)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta[3,2-f]benzofuran-1-yl)acetamide 1'-bromo-2',3',4'-trimethoxybenzo[5',6':4,5]-1H-(aR,1S)-1-acetamido-6,7-dihydrocyclohepta[3, 4-f]-1H-2-hydroxymethylindole 2-chloro-N-(6-cyano-7-hydroxy-6-(isopropoxymethyl)-6,7-dihydro-5Hdibenzo[a,c][7]annulen-5-yl)benzamide (R)-(+)-N-acetylolchinol 5-[N'-(3,5-difluorophenylacetyl)-L-alaninyl]amino-5,7-dihydro-6H-dibenzo[a,c]cyclohepten-6-ol N-(3,9,10,11-tetramethoxy-7-oxo-6,7-dihydro-5H-dibenzo [a,c][7]cyclohepten-5-yl)-2,2,2-trifluoroacetamide (S)-7-acetamido-6,7-dihydro-1,2,3-trimethoxy-7H-dibenzocycloheptene N-(2-iodo-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl)-acetamide N-(9,10-dimethoxy-7-oxo-6,7-dihydro-5H-dibenzo[a,c][7]cyclohepten-5-yl)-2,2,2-trifluoroacetamide N-(9-hydroxy-1,2,3-trimethoxy-5,6-dihydro-7H-di-benzo[a,c][7]annulen-7-yl)acetamide N-(1,2,3,9-tetramethoxy-5,6-dihydro-7H-dibenzo[a,c][7]annulen-7-yl)acetamide N-(3-hydroxy-9,10-dimethoxy-7-oxo-6,7-dihydro-5H-dibenzo[a,c][7]cyclohepten-5-yl)-2,2,2-trifluoroacetamide N-(3-hydroxy-9,10,11-trimethoxy-7-oxo-6,7-dihydro-5H-dibenzo[a,c][7]cyclohepten-5-yl)-2,2,2-trifluoroacetamide N-(3-hydroxy-2-iodo-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl)-acetamide